#United States #Elk Grove Village #Orsini #Gilead #Hepcludex

Orsini Takes the Lead as Specialty Pharmacy for Hepcludex®

In a significant development for patients suffering from chronic hepatitis delta virus (HDV) infections, Orsini, recognized for its expertise in rare disease pharmacy solutions, has been appointed as the contracted specialty pharmacy for Gilead's Hepcludex® (bulevirtide‑gmod). Approved by the U.S. Food and Drug Administration (FDA) as a first-in-class entry inhibitor, Hepcludex® offers hope to adults battling this severe form of viral hepatitis. This involves a subcutaneous injection targeting both individuals with compensated cirrhosis and those without cirrhosis.

The urgency behind this drug stems from the reality that approximately 40,000 Americans are currently affected by HDV. Known for its association with faster progression to liver damage, cirrhosis, and an elevated risk of liver cancer and mortality, HDV poses a significant threat to public health. While Hepcludex® has shown statistically significant improvements in clinical trials when compared to placebo, further confirmation of clinical benefits is necessary for continued FDA approval.

Orsini’s CEO, Brandon Tom, expressed great enthusiasm about this partnership with Gilead, underscoring the company’s commitment to the HDV community. He remarked, “We are incredibly honored to partner with Gilead to support the HDV community. At Orsini, our deep experience in rare diseases positions us to help remove barriers, simplify access to Hepcludex®, and ensure patients can receive this important therapy as quickly and seamlessly as possible.”

Orsini’s reputation in the field of rare diseases and genetic therapies dates back to 1987. With a mission focused on providing comprehensive and compassionate care, the pharmacy collaborates with biopharma innovators, healthcare providers, and payors to facilitate access to breakthrough treatments. Utilizing a high-touch care model, Orsini coordinates its efforts to ensure that no patient is overlooked. Its integrated services include pharmacy distribution, clinical management, and patient support tailored specifically for rare disease medications.

The organization is committed to removing obstacles that often hinder the timely access to therapies. With accreditations from prestigious entities such as the Accreditation Commission for Health Care (ACHC), URAC, and NABP, Orsini has also earned the Rare Disease Pharmacy Center of Excellence Designation from URAC, highlighting its quality of care in this specialized field.

As Orsini begins its role as the specialty pharmacy for Hepcludex®, patients can expect streamlined access to medication and personal support throughout their treatment journey. The service is designed to alleviate the burden on patients and their families as they navigate the complexities associated with managing HDV infections.

In conclusion, the collaboration between Orsini and Gilead not only leverages Orsini's extensive experience but also represents a proactive step towards enhancing outcomes for individuals grappling with the devastating impacts of HDV. As the healthcare landscape continues to evolve, partnerships like this will be crucial in ensuring that revolutionary therapies reach the patients who need them most.